It depends I think on if the FDA make a decision on 31 May (not sure if they do)
Or have the hearing and report back later with the outcome
In the grand scheme of things Sarepta's trouble/win may just be a minor distraction for ANP who has a lot of it's own issues and boxes to tick to move itself forward to somewhere that makes it attractive to buyers
ANP Price at posting:
6.4¢ Sentiment: Buy Disclosure: Held
